非小细胞肺癌中KRAS突变亚型及其他致癌通路中的共现突变
研究对4507例非小细胞肺癌(NSCLC)诊断样本行14基因二代测序,部分行FISH,另101例行扩展14基因测序,两例行全外显子测序。1078例KRAS突变患者中53.5%有至少一个额外突变,不同KRAS亚型共突变模式不同,EGFR和BRAF可靶向共突变各占1.2%。
要点
- 1078例KRAS突变NSCLC中53.5%合并至少一个其他致癌通路突变。
- 常见共突变为TP53 39.4%、STK11 19.8%、KEAP1 12.9%、ATM 11.9%。
- MET扩增15.4%,ERBB2扩增13.8%且仅见于G12C亚型。
核心结论
- KRAS突变NSCLC是遗传异质性亚组,癌症相关通路共突变频率高,部分与特定KRAS突变亚型相关。
- 这种多样性可能对理解KRAS突变NSCLC治疗结局差异和未来试验设计有启示。
研究设计与样本
- 对4507例NSCLC患者诊断样本行14基因二代测序,部分患者行荧光原位杂交(FISH)。
- 对101例患者行扩展14基因的二代测序,对2例患者行全外显子测序。
- 分子数据与临床数据相关联。
主要发现
- 共识别1078例KRAS突变患者,其中53.5%有至少一个额外突变。
- 不同KRAS突变亚型显示不同的共突变模式。
- 共突变包括TP53(39.4%)、STK11(19.8%)、KEAP1(12.9%)、ATM(11.9%)。
- MET扩增占15.4%,ERBB2扩增占13.8%且仅见于G12C亚型。
- 可靶向共突变罕见:EGFR占1.2%,BRAF占1.2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Although KRAS mutations in NSCLC have been considered mutually exclusive driver mutations for a long time, there is now growing evidence that KRAS-mutated NSCLC represents a genetically heterogeneous subgroup. We sought to determine genetic heterogeneity with respect to cancer-related co-mutations and their correlation with different KRAS mutation subtypes. METHODS: Diagnostic samples from 4507 patients with NSCLC were analyzed by next-generation sequencing by using a panel of 14 genes and, in a subset of patients, fluorescence in situ hybridization. Next-generation sequencing with an extended panel of 14 additional genes was performed in 101 patients. Molecular data were correlated with clinical data. Whole-exome sequencing was performed in two patients. RESULTS: We identified 1078 patients with KRAS mutations, of whom 53.5% had at least one additional mutation. Different KRAS mutation subtypes showed different patterns of co-occurring mutations. Besides mutations in tumor protein p53 gene (TP53) (39.4%), serine/threonine kinase 11 gene (STK11) (19.8%), kelch like ECH associated protein 1 gene (KEAP1) (12.9%), and ATM serine/threonine kinase gene (ATM) (11.9%), as well as MNNG HOS Transforming gene (MET) amplifications (15.4%) and erb-b2 receptor tyrosine kinase 2 gene (ERBB2) amplifications (13.8%, exclusively in G12C), we found rare co-occurrence of targetable mutations in EGFR (1.2%) and BRAF (1.2%). Whole-exome sequencing of two patients with co-occurring phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutation revealed clonality of mutated KRAS in one patient and subclonality in the second, suggesting different evolutionary backgrounds. CONCLUSION: KRAS-mutated NSCLC represents a genetically heterogeneous subgroup with a high frequency of co-occurring mutations in cancer-associated pathways, partly associated with distinct KRAS mutation subtypes. This diversity might have implications for understanding the variability of treatment outcome in KRAS-mutated NSCLC and for future trial design.
引用
- Scheffler M, Ihle MA, Hein R, et al. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. J Thorac Oncol. 2018. PMID: 30605727. doi:10.1016/j.jtho.2018.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。